Viridian Therapeutics to Present at the Ladenburg Thalmann 2021 Healthcare Conference
Rhea-AI Summary
Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on innovative treatments for serious diseases, announced that its CEO, Jonathan Violin, Ph.D., will present at the Ladenburg Thalmann 2021 Healthcare Conference on July 14, 2021, at 9:00 a.m. ET. The event will be held virtually, and the presentation can be accessed through Viridian's website. The company is known for its monoclonal antibody program, VRDN-001, targeting Thyroid Eye Disease (TED), which causes significant discomfort and potential blindness.
Positive
- None.
Negative
- None.
News Market Reaction – VRDN
In the trading session that priced this news, VRDN gained 0.29%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOULDER, Colo., July 07, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies, today announced that Jonathan Violin, Ph.D., President and Chief Executive Officer of Viridian, will present a company overview at the virtual Ladenburg Thalmann 2021 Healthcare Conference taking place July 13 – 14, 2021.
| Event: | Ladenburg Thalmann 2021 Healthcare Conference |
| Date: | Wednesday, July 14 |
| Presentation Time: | 9:00 a.m. ET |
The webcast information for this event will be accessible on the Events page under the Investors section of the Viridian Therapeutics website at www.viridiantherapeutics.com. A replay of the presentation will be archived on the website and available for approximately 90 days following the live event.
About Viridian Therapeutics
Viridian Therapeutics is a biotechnology company advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies. Viridian’s most advanced program, VRDN-001, is an anti-IGF-1R monoclonal antibody in development for TED, a debilitating auto-immune disease that causes inflammation and fibrosis within the orbit of the eye which can cause double vision, pain, and potential blindness. Patients with severe disease often require multiple remedial surgeries to the orbit, eye muscles, and eyelids. Viridian is based in Boulder, Colorado, and Waltham, Massachusetts. Learn more about Viridian and its programs at https://www.viridiantherapeutics.com/.
Follow us on Twitter @ViridianThera and on LinkedIn.
Viridian Contacts:
Investors:
Dan Ferry
LifeSci Advisors
617-430-7576
IR@viridiantherapeutics.com
Media:
Darby Pearson
Verge Scientific Communications
703-587-0831
PR@viridiantherapeutics.com